During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US, answered: Is transplantation still relevant? If yes, in which context?In this podcast, Lonial describes results from the FORTE (NCT02203643) and IFM 2009 (NCT01191060) trials, which investigated the use of triplet combinations with and without transplant. He warns of the 'siren song' of early MRD negativity that may lead one to believe novel agents are just as good as transplant. Lonial highlights that the focus needs to be on sustained MRD negativity; rates of which were higher in the patients who received a transplant. He also highlights two reasons for the discrepancy seen among early MRD negativity and sustained MRD negativity between patients who received a transplant and those who did not. Hosted on Acast. See acast.com/privacy for more information.

During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Eli Muchtar, Mayo Clinic, Rochester, US and Suzanne Lentzsch, Columbia University, New York, US. We asked, The challenges of monitoring organ response in AL amyloidosis: What has been achieved so far?The podcast focuses on both hematologic and organ response in amyloidosis, as well discussing the findings of a recent study. Hosted on Acast. See acast.com/privacy for more information.

Dr. María-Victoria Mateos discusses the progression from MGUS to MM, risk stratification for SMM, and clinical trials showing benefits of treating high-risk SMM. Early treatment of SMM is key in her cure roadmap, with two curative approaches in clinical trials.

During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR, answered: Does 'cure' have a different meaning in MM?In this podcast, Mohty discusses how the word 'cure' has different implications for young and older patients, and discusses the functional/operational cure for patients with standard- and high-risk disease. Mohty focuses on the importance of sustained MRD negativity on survival and why it should also be monitored by PET-CT. Seeing novel agent combinations reaching unprecedented results, he is hopeful that the cure rates will rise in both young and older patients with MM in the near future. Hosted on Acast. See acast.com/privacy for more information.

During the 2021 ASCO Annual Meeting, the Multiple Myeloma Hub spoke with Clifton C. Mo and Omar Nadeem, Dana-Farber Cancer Institute, Boston, US. We asked, How to treat first relapse in lenalidomide-refractory multiple myeloma (MM)?In this podcast, Mo and Nadeem discuss factors to be considered with regimen options for patients with lenalidomide-refractory MM. They discuss cardiac risk factors, lines of therapy, prognosis, and end the podcast on the topic of new agents. Hosted on Acast. See acast.com/privacy for more information.

During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Pieter Sonneveld, Erasmus MC, Rotterdam, NL. We asked, With the unprecedented results seen with novel therapies, what is needed to overcome the poor prognosis of high-risk multiple myeloma (MM)?In this podcast, Sonneveld discusses trial results presented during EHA2021 on the efficacy of novel treatments for patients with high-risk MM, a patient group associated with poor outcomes and shorter remission rates. He believes that identifying high-risk patients and selecting them for more intensive targeted maintenance treatment could be crucial in preventing relapse. Hosted on Acast. See acast.com/privacy for more information.

During the European School of Haematology (ESH) 3rd How to Diagnose and Treat Multiple Myeloma conference, the Multiple Myeloma Hub spoke to Xavier Leleu, Poitiers University Hospital, Poitiers, FR. We asked, When BCMA-directed therapy is not an option, how should we treat late relapse?Leleu discusses three alternatives to anti-B-cell maturation antigen (BCMA) directed therapies, including alternative drugs (provided the patient is nonrefractory), enrolment to clinical trials investigating new treatments, and the use of developing agents administered in the context of compassionate use. Hosted on Acast. See acast.com/privacy for more information.

During the 3rd European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Professor Philip McCarthy, Roswell Park Comprehensive Cancer Center, Buffalo, US. We asked, What do you need to remember when facing CAR T-cell toxicities? In this podcast, McCarthy discusses the two main chimeric antigen receptor (CAR) T-cell toxicities: cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS). Initially, McCarthy lists what to look out for in terms of symptoms in this highly practical podcast episode. He then describes the timeline for the appearance of these adverse advents and the current treatment strategies that are being used. Hosted on Acast. See acast.com/privacy for more information.

During the National Comprehensive Cancer Network (NCCN) 2021 Annual Conference, the Multiple Myeloma Hub spoke to Natalie S. Callander, University of Wisconsin-Madison, Madison, US and Shaji K. Kumar, Mayo Clinic, Rochester, US. We asked, What are the key additions to the new NCCN guidelines for multiple myeloma?Callander and Kumar discuss the inclusion of new diagnostic tools, such as MRD testing, risk-stratification for MM and it’s precursor stages, and changes to treatment regimens for newly diagnosed and relapsed MM. Callander also describes an important update for the recommendation of the combination of daratumumab, cyclophosphamide, bortezomib, and dexamethasone for the treatment of amyloidosis, providing supporting data from the phase III ANDROMEDA trial. They finish by discussing risk stratification and treatment intervention updates for smoldering MM. Hosted on Acast. See acast.com/privacy for more information.

During the 2nd European Myeloma Network Meeting, the Multiple Myeloma Hub spoke to Professor Graham Jackson, Newcastle University, Newcastle upon Tyne, UK, and Professor Philippe Moreau, CHU de Nantes, Nantes, FR. We asked, If maintenance after induction reduces therapy options at relapse, is it still worth it?Currently, the only approved maintenance therapy for multiple myeloma is lenalidomide. When answering whether this treatment is worth it, Jackson provides meta-analysis results of the CALGB 100104, IFM 2009, and Myeloma XI studies demonstrating improved progression-free survival by around 20−30 months compared with placebo. Jackson and Moreau then discuss alternative treatments in patients who are refractory to lenalidomide, focusing on optimizing carfilzomib + dexamethasone, daratumumab, bortezomib + dexamethasone, and pomalidomide + dexamethasone-based regimens. Hosted on Acast. See acast.com/privacy for more information.